Biosimilars - Through the Physician’s Lens

Biosimilars - Through the Physician’s Lens

Summary

Since their introduction within the past few decades, biosimilars outrivaled biologics in reducing treatment costs and improving access to therapies for chronic conditions such as cancer, rheumatoid arthritis (RA), and diabetes. Nevertheless, while biosimilars are increasingly recognized for their clinical and economic benefits, their uptake has been slower than anticipated in some markets. The physician’s role in shaping the future of biosimilar use is undeniable, given their influence on prescribing practices and patient trust. In this report, GlobalData examines biosimilar use, focusing on physician perceptions. The report provides insights into biosimilar uptake, substitution patterns, and use across the eight major markets (8MM: US, France, Germany, Italy, Spain, the UK, Japan, and China).

• Biosimilar uptake varies across therapeutic areas and regions, driven by factors such as regulatory policies and market dynamics.
• The global biosimilar market is forecast to reach $24.75 billion in sales by 2030 with the US driving the most sales.
• Across all markets surveyed, healthcare providers (HCPs) confirmed that their biosimilar prescriptions are going to increase in the next five years.
• Physicians generally support substituting branded biologics with biosimilars.
• If cost was not the main factor, close to 40% of physicians would prefer to use branded biologics for their patients.
• Despite market differences, most physicians agreed that patients should have an option to choose between biologics and their biosimilars.
• China has strong potential in the biosimilars market but may face tough global competition.
• The US’s IRA may have limited impact on biosimilars, while the BIOSECURE Act may increase their prices due to manufacturing and supply chain disruptions.

• Physicians' attitude and opinions on biosimilar prescription, substitution, and interchangeability
• Past and future uptakes of biosimilars
• Barriers to biosimilar uptake
• Cost consideration of biosimilar prescription
• Patients' preference on branded biologics and biosimilars
• Differences on biosimilar across markets

• Assess healthcare professionals’ attitude towards biosimilar prescription.
• Better understand the barriers to biosimilar uptake.
• Capture physicians’ opinions on substitution and interchangeability.
• Better understand patients’ preferences.
• Assess past and future biosimilars uptake.
• Gain a better understanding of cost consideration when prescribing drugs.
• Explore the differences across markets.